<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849992</url>
  </required_header>
  <id_info>
    <org_study_id>20115</org_study_id>
    <nct_id>NCT00849992</nct_id>
  </id_info>
  <brief_title>Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy</brief_title>
  <official_title>Randomized Prospective Study Comparing 5% Imiquimod and Photodynamic Therapy for Actinic Cheilitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Actinic cheilitis is a common precancerous lesion of the lip. The purpose of this study is to
      compare imiquimod 5% therapy and photodynamic therapy. The data will include effect data,
      histology (skin analysis), epidemiological data and follow-up data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study comparing imiquimod 5% with photodynamic therapy for actinic cheilitis.
      Histological, efficacy, epidemiological and clinical data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical and pathological complete cure rates.</measure>
    <time_frame>3 and 12 months after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical, safety, epidemiological and histopathological data</measure>
    <time_frame>post-treatment</time_frame>
    <description>Through collecting patient data and post-treatment biopsy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Actinic Cheilitis</condition>
  <arm_group>
    <arm_group_label>Imiquimod 5%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients randomized to this arm will receive treatment with imiquimod 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photodynamic therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5%</intervention_name>
    <description>Imiquimod 5% cream used three days a week for 4 weeks</description>
    <arm_group_label>Imiquimod 5%</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy</intervention_name>
    <description>Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.</description>
    <arm_group_label>Photodynamic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical findings of actinic cheilitis.

          -  Histological findings demonstrating epithelial changes equal to or greater than mild
             epithelial dysplasia in severity (mild - moderate - severe).

          -  Age above 18.

          -  Willingness to take post-treatment biopsy.

        Exclusion Criteria:

          -  Disorders predisposing to photosensitivity (porphyria, SLE).

          -  Pregnancy or nursing.

          -  Known allergy to any excipients in the study creams.

          -  prescribed topical retinoids, 5-fluorouracil, cryodestruction, surgical excision and
             curettage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein H Sundstr√∏m, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic cheilitis</keyword>
  <keyword>Imiquimod 5%</keyword>
  <keyword>Photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cheilitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

